ABSTRACT-Since the discovery of the most potent vasoconstrictor peptide, endothelin, in 1988, explosive investigations have rapidly clarified much of the basic pharmacological, biochemical and molecular biological features of endothelin, including the presence and structure of isopeptides and their genes (endothelin-1, -2 and -3), regulation of gene expression, intracellular processing, specific endothelia converting enzyme (ECE), receptor subtypes (ETA and ETB), intracellular signal transduction following receptor activation, etc. ECE was recently cloned, and its structure was shown to be a single transmembrane protein with a short intracellular N-terminal and a long extracellular C-terminal that contains the catalytic domain and numerous N-glycosylation sites. In addition to acute contractile or secretory actions, endothelin has been shown to exert long-term proliferative actions on many cell types. In this case, intracellular signal transduction appears to converge to activation of mitogen-activated protein kinase. As a recent dramatic advance, a number of non-peptide and orally active receptor antagonists have been developed. They, as well as current peptide antagonists, markedly accelerated the pace of investigations into the true pathophysiological roles of endogenous endothelin-1 in mature animals; e.g., hypertension, pulmonary hypertension, acute renal failure, cerebral vasospasm, vascular thickening, cardiac hypertrophy, chronic heart failure, etc. Thus, the interference with the endothelin pathway by either ECE-inhibition or receptor blockade may
Endothelin, a 21-amino acid peptide, was initially identified in 1988 by Yanagisawa et al. as a potent vasoconstrictor and pressor substance isolated from the culture supernatant of porcine aortic endothelial cells (1) . This peptide, which was originally termed porcine endothelin and is now referred to as endothelin-1, has a molecular weight of 2492, free amino and carboxyl termini, and two intrachain disulfide bonds between residues Cys'-Cys15 and Cys3-Cys11.
Since the initial isolation, endothelin-1 has been shown to be encoded in the genome of several mammalian species, including humans. Analysis of the human genome revealed that two other endothelin isopeptides are encoded in separate genes, endothelin-2 and endothelin-3 (2) . These isoforms of endothelin show a high degree of primary amino acid sequence identity; all are 21-amino acid polypeptides, containing two intrachain disulfide bonds, and all contain an identical hydrophobic C-terminal hexapeptide sequence. The three endothelin isopeptides share a remarkable resemblance, both in structure and biological activity, to the sarafotoxins, a family of isopeptides isolated from the venom of the snake Atractaspis engaddensis, suggesting a possible common evolutionary origin (3) .
Although vascular endothelial cells are the major source of endothelin-1, the genes encoding the three endothelin isopeptides are expressed with different patterns in a wide variety of cell types including cardiac myocytes, vascular smooth muscle cells, renal tubular epithelial cells, glomerular mesangial cells, glial cells, pituitary cells, macrophages and mast cells, suggesting that the peptides may participate independently in complex regulatory mechanisms in various organs (2, 4) . In addition to causing contraction of vascular tissues, endothelin isopeptides exert pleiotropic effects on non-vascular tissues, e.g., respiratory and gastrointestinal tissues, kidney, endocrine glands, and peripheral and central nervous system, and are considered to be closely related to physiological control as well as having pathophysiological implications in various tissues (5, 6) . With such a variety of actions, it is not hard to understand why the endothelin isopeptides have stimulated much research in both academia and industry. Recent advances in the development of endothelin receptor antagonists have accelerated the pace of investigations of the true physiological and/or pathophysiological roles of endogenous endothelins in mature animals and humans. As a result, the physiological and pathophysiological roles of endothelin-1 have been gradually uncovered. Nevertheless, there is still a paucity of comparative information on endothelin-2 and endothelin-3.
In this manuscript, we have reviewed the recent information on the molecular features of endothelin biosynthesis, receptors, intracellular biochemical processes following the receptor activation, etc. that have currently been controversial. The use of many potent endothelin receptor agonists and antagonisits has yielded important recent data indicating that endothelins are likely to be critically involved in the etiology and pathology of cardiovascular diseases.
Finally, the production of endothelin-deficient (7) and endothelin-receptor-deficient (8) mice by means of gene targeting has shown unexpectedly that the endothelins have crucial roles in normal embryonic development. Endothelin-1-deficient mice have craniofacial and cardiac abnormities at birth and die of respiratory failure soon afterwards (7) . In contrast, ETB receptor-deficient mice exhibited aganglionic megacolon associated with coat color spotting, resembling a hereditary syndrome of humans, Hirschsprung's disease (9) . Surprisingly, a targeted disruption of endothelin-3 resulted in the development of exactly the identical syndrome, suggesting that interaction of endothelin-3 and the ETB receptor is essential for development of enteric neurons and epidermal melanocytes (10) . These molecular biological studies open up an entirely new field of research on endothelins, but are beyond the scope of this review.
11-1. Endothelin gene and regulation of its expression
The human endothelin-1 gene contains five exons, four introns, and 5'-and 3 '-flanking regions, and spans approximately 6.8 kb of DNA. Each of the five exons encodes a portion of preproendothelin-1.
The primary transcription start site in endothelial cells was mapped by S 1 nuclease protection to a position 98 base pairs downstream from the CAAT box and 31 base pairs from the TATAA box (2) . Several characteristic regulatory elements are found within the endothelin-1 gene: motifs of the consensus binding sequence for the transcription factor nuclear factor-1 (11) , four copies of the hexanucleotide CTGGGA, the acute phase reaction regulatory element, and sequences highly homologous to the octanucleotide consensus AP-1/Jun-binding site (2, 12) . The presence of an AP-1/Jun-binding site in the 5 '-flanking region could explain the rapid induction of endothelin-1 mRNA following treatment of endothelial cells with phorbol ester.
The regulation of expression of endothelin-1 mRNA in cultured endothelial cells has been studied extensively. Increased mRNA levels have been observed after treatment of the cells with growth factors and cytokines such as thrombin (13) , transforming growth factor (TGF)-r3 (14) , tumor necrosis factor (TNF)-a (15), interleukin (IL)-1 (16) and insulin, or with vasoactive substances (17, 18) such as norepinephrine, angiotensin II, vasopressin, bradykinin, oxidized or acetylated low density lipoprotein (LDL). The increase in expression of endothelin-1 mRNA induced by thrombin, angiotensin II, and vasopressin has been shown to be promoted by an increase in intracellular Ca 2+ concentration and activation of protein kinase C (PKC) via GTP-binding protein following stimulation of their receptors (13, 19) . However, the mechanisms of regulation of mRNA expression by other substances remain to be elucidated. Although no SSRE (shear stress responsive element) was detected in the endothelin-1 gene, mRNA expression and endothelin production in endothelial cells are regulated by fluid shear stress: high shear stress (25 dynes/cm2) sharply decreases mRNA levels (20, 21) , whereas low shear stress (5 dynes /cm2) increases endothelin-1 mRNA expression (22) . Pulsatile stretch also causes enhanced production of endothelin-1 in endothelial cells (23) . Shear stress appears to regulate endothelin-1 gene transcription via an upstream cis element by a distinct mechanism not dependent on PKC or cAMP pathways (24) . In contrast, the expression of endothelin-1 mRNA is inhibited by endothelium-derived relaxing factor (nitric oxide), prostacyclin and atrial natriuretic peptide, presumably via cGMP-mediated inhibition of phosphatidyl inositide metabolism (25) . Heparin also decreases endothelin-1 mRNA expression via inhibition of PKC (26) . message and the ability of cycloheximide to cause superinduction (2, 12) (Fig. 1) .
All of these characteristics of the endothelin-1 gene bear a resemblance to those of the so-called early response genes such as various protooncogenes. ' Human preproendothelin-1 is a 212-amino acid protein that is proteolytically cleaved, as in the case of many bioactive peptides, at paired basic amino acids, specifically at adjacent positions of Lys51-Arg52 and Arg92-Arg93 by a dibasic-pairspecific endopeptidase, thereby producing a 38-amino acid residue intermediate peptide, termed "big endothelin-1". As an endopeptidase processing preproendothelin-1, furin appears to be a definite enzyme (27) . Big endothelin-1 is subsequently cleaved at Trp21-Va122 by a novel endopeptidase, which appears to be specific for endothelin and was putatively termed endothelin converting enzyme (ECE) (Fig. 2) . In vascular endothelial cells, endothelin-1 is secreted via the constitutive pathway, and the rate-limiting step of its biosynthesis is thought to be at the level of transcription (1). Endothelin-1 gene expression in vascular endothelial cells has been shown to be stimulated by a number of chemical stimuli as described above.
Whether big endothelin-1 is cleaved intracellularly or extracellularly has been a matter of controversy. Endothelial cells possess a membrane-bound neutral metalloprotease exhibiting ECE activity (28) , which is inhibited by a relatively high concentration of phosphoramidon (29) . Both in vivo and in vitro, exogenously applied big endothelin-1 is rapidly converted, suggesting that the conversion takes place at the cell surface (30) . The conversion from big endothelin-1 to endothelin-1 is essential for exertion of biological activity, because the pressor action of big endothelin-1 was almost completely inhibited by a relatively large dose of phosphoramidon (31, 32) . In the culture medium of endothelial cells, the c-terminal fragment-like material of big endothelin-1 was detected at a similar level to endothelin-1, and a small amount of big endothelin-1 was also detected, indicating that big endothelin-1 may be cleaved when it goes across the endothelial cell membrane (29, 33) . However, the precise mechanism of conversion still remains to be elucidated. 11-3. Characterization and cloning of endothelin converting enzyme Recently, by sequencing the ECE fragment purified from bovine adrenal cortex and using a cDNA product obtained by reverse transcription-polymerase chain reaction (RT-PCR) as a probe, the ECE gene was cloned from bovine adrenal cortex cDNA libraries (34) . The structure of the ECE gene reflects a 758-amino acid metalloprotease enzyme, containing a single membrane-spanning sequence with only a 56-residue N-terminal cytoplasmic tail and an extracellular C-terminal of 681 amino acid residues that contains the catalytic domain. Amino acid residues 593 -601 match the highly conserved consensus sequence of a zinc-binding motif, HEXXH, which is shared by many known metalloproteases. The ECE protein has ten predicted sites for N-glycosylation in the extracellular domain, suggesting that ECE behaves as a highly glycosylated protein (Fig. 3) . Northern blot analysis demonstrated a ubiquitous distribution of a 4.4-kb fragment of mRNA for this enzyme, with the highest expression in the endothelium, ovary, testis and adrenal medulla. At the same time, a cDNA coding for another ECE was cloned from rat lung (35) and bovine vascular endothelial cells (36) . The 754-amino acid sequence deduced from the longest open reading frame of the cloned rat cDNA exhibits quite similar characteristics to that of ECE from bovine adrenal cortex, having a single membrane-spanning sequence, consensus sequences of a zinc-binding motif and catalytic domain, and N-glycosylation sites. These enzymes possess more than 90% primary amino acid homology and are now termed ECE-1. They appear to be associated with the plasma membrane and Golgi complex and to process big endothelin-1 more efficiently than either big endothelin-2 or big endothelin-3, suggesting the possible existence of multiple substrate-specific mammalian isozymes. Furthermore, certain endothelin-producing cell types, most notably neurons, do not exhibit expression of ECE-1 mRNA, again suggesting the possibility that different ECE isozymes may be expressed in neural tissues.
From bovine endothelial cell cDNA libraries, a novel ECE was cloned using a RT-PCR product against bovine adrenal cortex mRNA (37) . The enzyme termed ECE-2 is sensitive to phosphoramidon and converts big endothelin-1 more efficiently than big endothelin-2 or big endothelin-3, but exhibits the following striking differences from ECE-1: 1) The sensitivity of ECE-2 to phosphoramidon is 250-fold higher than that of ECE-1, while the sensitivity to FR901533 is similar. 2) ECE-2 has an acidic optimum pH of pH 5.5, which is in sharp contrast to the neutral optimum pH of ECE-1. Furthermore, Northern blot analysis revealed that neural tissues, such as the cerebral cortex, cerebellum and adrenal medulla, show the highest expression of ECE-2 mRNA. These results suggest the possibility that ECE-2 may be the major ECE in neurons, glia, and certain neuroendocrine cells.
Achieving proper characterization of the pathways involved in endothelin biosynthesis has proved to be a more difficult goal than might have been predicted. After more than six years, the cloning and characterization of ECE have finally been successfully achieved. ECE is considered to be a potential target for selectively interrupting the biosynthesis of endothelin; although this approach has proven to be extremely difficult, an N-and C-terminaltruncated analogue of big endothelin-1 , [Phe22] big endothelin-1 [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] , was recently shown to be a potent inhibitor of ECE-1, being at least 30-fold more potent that phosphoramidon in blocking big endothelin-linduced vasoconstriction in the kidney (38) .
When endothelin-1 was intravenously administered as a bolus, it disappeared quite rapidly from the bloodstream with a half-life of a few minutes (39, 40) . Furthermore, more than 65% of the endothelin-1 in the perfusate of isolated guinea pig lung was lost in one passage (40) . These results suggest that endothelin-1 may be quickly eliminated from the bloodstream by an uptake mechanism into various tissues, particularly the lung.
III-1. Classification of receptor subtypes
It was originally shown that intravenously administered endothelin-1 produced an initial transient fall and a subsequent prolonged elevation of systemic blood pressure in anesthetized rats (1) . The initial depressor response and the later pressor response are thought to be mediated by different mechanisms; while endothelin-1 is more potent than endothelia-3 in vasoconstrictive activity, both isopeptides are almost equipotent with respect to the initial depressor activity (2) . A straightforward interpretation of these findings is that the receptors mediating these opposing responses may be different: one is a vascular smooth muscle receptor with a strong preference for endothelin-1 over endothelin-3, and the other is an endothelial cell type receptor to which both peptides bind equally. A similar dissociation of the pharmacological potency order of the three endothelin isopeptides has also been observed in a variety of tissues other than the vascular system.
Endothelin-induced responses may be divided into two major groups, according to the pharmacological potency order of the three isopeptides. In the first group of responses, which includes vasoconstriction, bronchoconstriction, uterine smooth muscle contraction and stimulation of aldosterone secretion, endothelin-1 and -2 act as far more potent agonists than endothelin-3. In the second group, which includes endothelium-dependent vasorelaxation and inhibition of ex vivo platelet aggregation, the three isopeptides have almost equal potency. These observations suggest that there are at least two distinct ET receptors mediating these two distinct groups of pharmacological responses (Table 1) .
Cross-linking experiments and binding studies with radiolabeled endothelin in various tissues provided the first biochemical evidence for the existence of multiple endothelin binding sites (54, 55) . In other experiments on radioligand affinity in membrane fractions prepared from vascular smooth muscle cells (46) , chick heart (55), rat lung (56) , rat mesangial cells (57) , human placenta (58) and bovine cerebellum (59), the existence of at least two distinct subtypes of endothelin receptor was also suggested by the different relative affinities of the endothelin isopeptides.
111-2. Cloning of cDNA encoding endothelin receptor
Two cDNA clones that encode endothelin receptors have been isolated from rat (60) and bovine (61) lungs simultaneously by employing direct expression cloning techniques. Another endothelin-receptor cDNA was also cloned from rat A10 cells (62) and porcine cerebellum (63) . Subsequently, human homologs of these receptors were isolated by cross-hybridization using these cDNAs as probes (64, 65) . According to the relative binding affinities of the three endothelin isopeptides for the receptors when expressed in transfected mammalian cells, these receptors can be classified into two groups. The order of affinity of endothelins for the first receptor type, designated ETA, is endothelin-1 >_ endothelin-2 endothelin-3. The second receptor type, designated ETB, shows equipotent affinity for all three endothelins and for sarafotoxins (5) . These results are consistent with the results of previous pharmacological and biochemical experiments and herein provide the molecular basis for the existence of two distinct endothelin receptor subtypes. Although the involvement of the ETB receptor in endothelin-l-induced vasoconstriction is indisputable, particularly in veins (66) (67) (68) , endothelin receptors are generally classified into two major groups in vascular tissues as illustrated in Fig. 4 .
Are there still more subtypes of endothelin receptor? In pharmacological and radioligand binding experiments, the existence of a receptor specific for endothelin-3 was first demonstrated in cultured bovine endothelial cells (69) and cultured rat anterior pituitary cells (70) . Subsequently, much pharmacological evidence has accumulated to suggest that there may exist further subtypes or sub-subtypes of endothelin receptor (71, 72) . However, there has been no report so far on isolation of the cDNA clone encoding a receptor specific for endothelin-3 from mammalian tissues. Furthermore, Southern blot analysis of human genomic DNAs with cloned cDNA probes suggests tnat eacn enuotneiin receptor uLiwi piuuc can cross-hybridize with only two different genomic DNA fragments, even under the condition of reduced stringency (65) . Thus, it appears that mammalian genomes contain only two closely related genes that encode endothelin receptors, which may correspond to ETA and ETB, and it is likely that the third receptor gene, if it exists in mammalian genomes, has little similarity to the two cloned receptors. From the dermal melanopnore or Aenopus iaevis, a receptor has been cloned that shows functional selectivity for endothelin-3 over endothelin-1, and this was termed ETc. This receptor has 47% and 53% primary amino acid homology to mammalian ETA and ETB receptors, respectively (73) . However, the difference in affinity to the expressed receptor between endothelin-3 and endothelin-1 was not as great as expected. Furthermore, the expressed receptor showed only low affinity for both endothelin-3 and endothelin-1, with Kd values several orders of magnitude lower than those of most published receptors for both endothelin isopeptides. Another endothelin receptor has been cloned from Xenopus laevis heart (74). The isolated cDNA encoded a protein of 415 amino acids that showed 74%, 60% and 50% primary amino acid sequence identity with human ETA, ETB and Xenopus laevis ETA receptors, respectively. The characteristics of this receptor are similar to those of the mammalian ETA receptor in that endothelin-3 showed weaker affinity to it than endothelin-1, and sarafotoxin 6c showed hardly any .. lY:...: The ETA receptor on smooth muscle has high affinity for ET-1, but low affinity for ET-3, inducing vasoconstriction. The ETB receptor on the endothelium has equal affinity for both peptides, releasing endothelium-derived relaxing factor (EDRF) or prostacyclin. Responses induced by ETs depend on the balance of activities at ETA and ETB receptors.
111-3. Regulation of receptor expression
Exposure of cultured smooth muscle cells (75) , Swiss 3T3 cells (76) and glomerular mesangial cells (77) to endothelin-1 for a long time causes a marked decrease in 125I -endothelin-1 binding sites , indicating an autologous down-regulation of endothelin receptors. As observed with other vasoconstrictor substances, internalization of the endothelin receptor complex has been proposed as the mechanism for down-regulation (78). After internalization, the ligand-receptor complex is thought to be sequestered into lysosomal compartments where the acidic environment promotes ligand dissociation (75) .
In a rat osteosarcoma cell line (ROS 17/2 cells), rapid homologous down-regulation (within several hours of exposure to endothelin-1) of the ETB-receptor mRNA has been demonstrated (79). This decrease in ETB-receptor mRNA was mimicked by addition of either phorbol esters, ionomycin or dibutyryl cAMP (80) to the culture medium. As endothelin-1 induced the production of intracellular cAMP and hydrolysis of phosphoinositides, the homologous down-regulation of ETB-receptor mRNA may be mediated by the action of second messangers induced by endothelin-1. Further investigation using actinomycin D revealed that the down-regulation of ETBreceptor mRNA by endothelins possibly results from a decrease in the stability of ETB-receptor mRNA rather than from inactivation of mRNA transcription. On the contrary, the up-regulation of ETB receptors has been reported. In rat cardiomyocytes, the up-regulation of ETB-receptor mRNA induced by angiotensin II, which is probably mediated through stimulation of the AT1 receptor, has been demonstrated (81). Interestingly, in rat type-1 astrocytes, it has been shown that the expression of ETB-receptor mRNA is dramatically up-regulated by DBcAMP-induced cytodifferentiation (82). This upregulation of ETB-receptor mRNA is also observed in cytodifferentiated astrocytes induced by brain extract, which does not affect intracellular cAMP concentration (83), indicating that an increase in cAMP does not directly regulate the expression of ETB-receptor mRNA in astrocytes. Thus, the expression level of ETB-receptor mRNA in astrocytes may depend on the state of differentiation. As for the expression of ETA-receptor mRNA, the up-regulation of ETA-receptor mRNA induced by cAMP (84) . Further investigation will lead to a better understanding of the molecular mechanism for the tissuespecific expression of the ETR-gene family.
111-4. Intracellular signal transduction
The endothelins are involved in diverse biological processes, such as contraction of various tissues including vascular smooth muscle, neuromodulation, and cellular proliferation, as well as in certain pathophysiological conditions including cardiac and renal failure, which may be attributable to the existence of a number of receptor subtypes or G-protein-mediated activation of different signal transduction pathways, or the combined action of these two mechanisms (89).
Functionally, both ETA and ETB receptors are capable of coupling to various GTP-binding proteins (Gq, Gs, Gi, Go, etc.), suggesting that the down-stream signal transduction may differ depending on the type of GTPbinding proteins coupled. The activation of phospholipase C (PLC), the most generalized pathway in various tissues (90, 91), causes phosphatidyl inositol hydrolysis and rapid formation of 1,4,5-inositol triphosphate (IP3), and sustained accumulation of 1,2-diacylglycerol (DG (95) . Although the precise mechanism remains to be elucidated, the influx of extracellular Ca2+ secondary to stimulation of endothelin receptors may be mediated through pertussis toxin (PTX)-sensitive GTP-binding protein (96) . The cation channels might be opened either by direct coupling with the GTP-binding protein subunit or via a certain intracellular signal transduction pathway.
As the short-term changes in cell function produced by endothelin receptor activation, in addition to the increase in [Ca 2+]i, activation of phospholipase A2 (97) and D (98) and arachidonic acid metabolism have been demonstrated. The activation of phospholipase D appears to contribute to sustained DG accumulation, which may lead to prolonged activation of PKC (99) . In vascular smooth muscle and cardiac muscle cells, a change in intracellular pH (alkalinization) is also induced via stimulation of Na+-H+ exchange, which seems to be a consequence of PKC activation (100) .
In addition to being a potent vasoconstrictor, endothelin-1 is a potent mitogen in cultured vascular smooth muscle cells (101) , cardiac myocytes (102), glomerular mesangial cells (103) and other cells. Endothelin-1 also induces the expression of several proto-oncogenes (c fos, c-myc, c jun) (104) . A variety of mitogenic stimuli activate the intracellular kinase cascade including the sequential activation of raf-1, mitogen-activated protein kinase (MAPK) kinase, MAPK and S6 kinase II. In this cascade, MAPK, a 42/44 kDa serine / threonine kinase, is a key component. MAPK phosphorylates a set of proteins involved in the development of a mitogenic response, including S6 kinase II, the products of proto-oncogenes c-myc and c jun, and the transcription factor p62TCF, suggesting that MAPK activation is a necessary G1 event for mitogenesis. The activation of ET receptors (ETAR and ETBR) by endothelin-1 actually leads to MAPK activation (105) . In an attempt to elucidate the mechanisms for endothelin-induced mitogenesis, endothelin-l-induced MAPK activation has been investigated. MAPK activation secondary to stimulation of the receptor, which belongs to the G-protein-linked rhodopsin type of receptor superfamily, was recently suggested to be mediated not only through the PKC-dependent pathway but also through the PTX-sensitive, G;~1 / ras-dependent pathway which is initiated by a tyrosine phosphorylation event (Shc-Grb2 complex formation) common to receptor tyrosine kinases (RTK). As mentioned above, endothelin receptors may be coupled to PLC and thereby lead to activation of PKC in various types of cells. Thus, it is easily assumed that endothelin-l-augmented MAPK activation might be regulated by PKC activation. Indeed, ET-1-augmented MAPK activation was significantly inhibited by PKC down-regulation (106, 107) . In addition, it has also been demonstrated that endothelin-l-augmented MAPK activation is PTX-sensitive (108) and accompanied by Shc-Grb2 complex formation (109) . On the other hand, it has been revealed that endothelin-l-induced ras activation is insensitive to PTX (110) and that the ras / MAPK pathway stimulated by endothelin-1 is mediated by ligand-independent transactivation of epidermal growth factor (EGF) receptor, one of the RTK (111 MAPK activation involves Gi / Shc-Grb2 complex formation / ras / MAPK cascade in series. Incidentally, it has been demonstrated that both ETAR and ETBR are able to couple to Gig which mediates activation of the ras / MAPK pathway (112) . A plausible model of the mechanism for endothelin-l-augmented MAPK activation is shown in Fig. 5 . IV-1. Peptide antagonists In order to develop new agonists and antagonists, as in the case of many bioactive peptides, modification of the endothelin and sarafotoxin amino acid sequences was attempted first and resulted in not only production of a series of agonists with varying potency, but also gave rise to a number of antagonists that were either selective or nonselective for the endothelin receptor subtypes. An important milestone in the development of useful tools for the study of endothelin was the isolation of a cyclic pentapeptide, BE-18257B, from the fermentation products of Streptomyces misakiensis (113) . Further modification of BE-18257B has led to the identification of the cyclic pentapeptide BQ-123 (Banyu, Tokyo) with a higher affinity for the ETA receptor (114) . Because of its competitive and selective nature, high potency and aqueous solubility (115) , BQ-123 has been widely used not only for in vitro pharmacological as well as biochemical studies, but also for the investigation of potential physiological and/or pathophysiological roles of endogenous endothelin. The cyclic hexapeptide TAK-044 (Takeda, Osaka) is a synthetic compound that exhibits antagonistic activity against both ETA and ETB receptors (116) (Fig. 6 ).
Subsequent structure-activity studies have led to the development of a series of potent ETA-receptor-selective linear tripeptide antagonists, FR 139317 (Fujisawa, Osaka) (117), PD151242 (Parke-Davis, Morris Plains, NJ, USA) (118) , and the hexapeptide TTA-386 (Takeda) (119) . Further modifications along these lines resulted in the production of ETB-receptor-selective agonists, BQ-3020 (Banyu) and IRL 1620 (120) (Ciba-Geigy, Basel, Switzerland), and an ETB-receptor-selective antagonist BQ-788 (Banyu) (121) . IRL2500 (Ciba-Geigy) (122) is another linear triptide exhibiting ETB-receptor-selective antagonistic actions. The linear hexapeptide PD145065 (Parke-Davis) (123) exhibits antagonistic activity against both ETA and ETB receptors. These peptide agonists and antagonists have been used in a wide variety of pharmacological and biochemical investigations on endothelin isopeptides (Fig. 7) . Although small, relatively potent and selective peptide antagonists of endothelin receptors have proven to be extremely valuable tools for characterization of the endothelin receptors and for the determination of their tissue distribution, there are well-known limitations of the use of peptides in vivo for the chronic treatment of animal disease models and for clinical application in human patients. Thus, much effort has been directed toward the discovery of nonpeptide endothelin receptor antagonists. produced by structural modification of a sulfonamide lead compound first synthesized as part of an antidiabetic effort and was identified as a nonselective antagonist of endothelin receptors. While Ro 46-2005 had no effect on blood pressure in normotensive rats, it did show a longlasting blood pressure-lowering effect when orally administered as a bolus to sodium-depleted squirrel monkeys (10 to 100 mg/kg). This was the first demonstration that oral administration of an endothelin receptor antagonist is actually efficacious in lowering systemic blood pressure. Subsequent structure-activity relationship of this series led to the discovery of Ro 47-0203, bosentan (Hoffmann-La Roche), a far more potent and more ETA-receptor-selective antagonist, with Ki values (affinity) of 6.5 and 343 nM for ETA and ETB receptors, respectively (125) . When administered either orally or intravenously, Ro 47-0203 inhibited both the initial transient depressor (ETB) response and the following prolonged pressor (ETA) response induced by i.v. injected endothelin-1.
Using 1H NMR-derived conformational models of ET-1, a rational approach was taken in search of new nonpeptide antagonists of endothelin receptors. Screening of a chemical bank led to the identification of SK&F 66861 (SmithKline Beecham, King of Prussia, PA, USA), another important lead structure of diphenylindane compounds (126) . Comparison of the three-dimensional structure of this compound to low-energy 1H NMR-based conformations of endothelin-1 suggested that the 1-and 3-phenyl groups of SK&F 66861 are mimics of a combination of two of the aromatic side chains of Try13, Phe14 and Trp21 in endothelin-1. Three-dimensional peptidomimetic simulation has been further continued. As a result, an extremely potent and highly specific nonpeptide endothelin receptor antagonist, SB 209670 (SmithKline Beecham), has been synthesized and characterized (127 
V-1. Hypertension
Endothelin-1 causes potent vasoconstriction an( prolonged elevation of blood pressure (1). Thus, endog enous endothelin-1 is assumed to modulate vascula tone and regional blood flow as a circulating hormone o to exert its actions locally within the vascular wall and of the endothelium in an autocrine or paracrine fashion Recently, it has been demonstrated that the intravenou infusion of TAK-044, an ETA/ETB antagonist, decrease( systemic blood pressure moderately and total periphera resistance markedly in healthy men, suggesting that endogenous endothelin-1 may play a fundamental physiological role in maintenance of peripheral vascular tone and blood pressure (136) . This may be naturally extended to the possible implication of endothelin-1 in the development of systemic hypertension. If endothelin-1 is actually involved in the pathophysiology of hypertension, it could result from excessive production, reduced degradation, enhanced sensitivity or augmented responsiveness of vascular smooth muscle cells to the peptide (137), enhanced secretion of neurohumoral mediators of blood pressure regulation (norepinephrine, renin, angiotensin II, vasopressin, etc.) (138) , or diminished production of counterbalancing vasodilating mediators (endotheliumderived nitric oxide, prostacyclin, atrial natriuretic peptide, adrenomedulin, etc.) (139) . Endothelin-1 is also thought to cause vascular wall thickening due to its potent proliferative effects (140) . One or a combination of these activities of endothelin-1 may occur throughout the evolution of hypertension.
There are currently many reports regarding plasma levels of immunoreactive endothelin-1, and the results concerning the relationship between the plasma level and severity of hypertension are fairly divergent (141). These observations have gradually given rise to the negative supposition that endothelin-1 may not play any significant pathophysiological role in the development of hypertension. Nevertheless, even though no appreciable change in plasma levels was detected, a significant correlation between the concentration of immunoreactive endothelin-1 in vascular tissue and the level of systemic blood pressure has been demonstrated in deoxycorticosterone acetate (DOCA)-salt-induced hypertensive rats (142) and hyperinsulinemic hypertensive rats (143) . Furthermore, in the DOCA-salt-induced hypertension model, the elevated blood pressure was markedly reduced by ETA-receptor antagonists, BQ-123 (144) and FR-139317 (145) , and also by an endothelin-converting enzyme inhibitor, phosphoramidon (146) . In hyperinsulinemic hypertensive rats in which higher mesenteric endothelin-1 content appears to be brought about by increased plasma insulin, chronic endothelin-receptor blockade by bosentan, a ETA/ETB antagonist, caused a sustained decrease in systemic blood pressure without affecting the elevated plasma insulin level or mesenteric endothelin-1 content (143) .
Although the effects of peptide antagonists for endothelin receptors in spontaneously hypertensive rats (SHR) are currently controversial (147) (148) (149) , the nonpeptide antagonist SB209670 has recently been shown to exert significant and long-lasting hypotensive actions following intraduodenal administration in this particular model of hypertension (127) . The nonpeptide antagonists have been demonstrated to be effective in lowering blood pressure in various animal models of hypertension; e.g., sodium-depletion-induced hypertension in squirrel monkeys (124) , renal hypertension in dogs (150) and mouse renin transgenic ((mRen-2) 27) hypertensive rats (151) . In (mRen-2) 27 hypertensive rats, in which the fulminant hypertension is assumed to be brought about by the overproduction of angiotensin II (152), SB209670 infusion caused a sustained decrease in systemic blood pressure, the degree of which was identical to that caused by losartan, an angiotensin II receptor (AT1R) antagonist. The effects of SB209670 and losartan were additive, suggesting that accumulated endothelin-1, the overexpression of which might be induced by angiotensin II, may have also been concerned with this hypertension. From these results, it can be speculated that endogenous endothelin-1 may be implicated in the pathogenesis of some types of hypertension in humans. However, we have to await the results of further studies in humans to confirm these observations.
V-2. Pulmonary hypertension
Pulmonary hypertension (PH) is a progressively deteriorating condition characterized by an increase in pulmonary vascular tone, vasoreactivity, and enhanced proliferation of pulmonary vascular smooth muscle cells, thereby resulting in a marked increase in pulmonary vascular resistance and gradual onset of right ventricular hypertrophy (153) . PH has been shown to be associated with an increase in plasma endothelin levels (154) , and the plasma concentration of endothelin-1 correlated strongly with disease severity (155) (156) (157) . Furthermore, in young patients with pulmonary hypertension secondary to congenital heart disease, the elevated plasma levels of endothelin-1 dramatically decreased following successful surgical repair (158) . In patients with PH from a variety of causes (plexogenic pulmonary arteriopathy, reactive PH due to heart failure, and pulmonary arteriopathy), increased expression of endothelin-1-like immunoreactivity and its mRNA in pulmonary vascular endothelial cells has also been demonstrated (159) . These findings suggest that local production of endothelin-1 may contribute to the vascular abnormalities associated with this disorder. Similar observations were also made in patients with cryptogenic fibrosing alveolitis associated with PH (160) .
In rats with idiopathic pulmonary hypertension (IPH), an increase in endothelin-1 mRNA expression has been detected (161) . It was also found that cultured smooth muscle cells isolated from the pulmonary artery of rats with IPH not only overexpressed endothelin-1 mRNA but also produced more endothelin-1 peptide compared with cells from normotensive control rats (162) . The overproduced endothelin-1 contributed to the enhanced growth of pulmonary artery smooth muscle cells, particularly in the presence of 0.3% serum (162) . In monocrotaline-induced PH in rats, plasma endothelin-1 levels increased progressively and preceded the development of PH (163) . Infusion of BQ-123 reduced the progression of PH and right ventricular hypertrophy and prevented the characteristic thickening of the pulmonary arterial media. In this particular model of PH, it was shown that losartan was not efficacious (164) . The decrease in pulmonary arterial pressure by the infusion of FR139317, another selective ETA-receptor antagonist, was also demonstrated in beagle dogs with dehydromonocrotaline-induced PH (165) . Hypoxia is also known to induce PH, and bosentane was recently shown to prevent the development of PH in hypoxic rats (166) . Furthermore, continuous infusion of BQ-123 by an osmotic minipump over a two-week period in chronic heart failure rats with severe pulmonary hypertension (permanent coronary artery ligation) markedly reduced both right ventricular systolic pressure, a parameter of pulmonary arterial pressure, and central venous pressure, a parameter of systemic congestion, without significantly affecting left ventricular function during this period (167) . Thus, endothelin-1 can induce two events in the pulmonary circulation, vasoconstriction and arterial smooth muscle proliferation, both of which are key pathophysiological features of PH.
It has been demonstrated that endothelin-1 exerts an extremely potent constrictor action on isolated tracheal and bronchial smooth muscle (168, 169) . The bronchoalveolar levels of immunoreactive endothelin are increased in asthmatic patients (170, 171) . Bronchial epithelial cells obtained from asthmatics expressed preproendothelin-1 mRNA and released significant quantites of endothelin-1 into the culture medium, whereas those from normal humans did not (172) . The available evidence overall is suggestive that endothelin-1 is involved in the pathogenesis of asthmatic disease, but the true situation remains to be elucidated.
V-3. Acute renal failure
Acute renal failure (ARF), of either ischemic or nephrotoxic origin, is frequently characterized by a reduction in renal blood flow that may be associated with renal tubular dysfunction (173) . Endothelin-1 has been demonstrated to reduce both renal blood flow and glomerular filtration rate by acting as a potent renal vasoconstrictor (174) . There is now accumulating evidence that suggests the possible role of endothelin-1 in the pathogenesis of ARF after renal ischemia; e.g., increased plasma level of endothelin-1 in patients with ARF (175), elevated tissue level of endothelin-1 in postischemic kidney (176), and a time-dependent increase in endothelin-1 and -3 binding affinity at the renal ETA and ETB receptors during reperfusion after ischemia (177) . Administration of an antibody to endothelin-1 before renal artery clamping in rats has been shown to prevent the increase in periglomerular arteriolar resistance and the reduction in single nephron glomerular filtration rate that occur for up to 48 hr following clamping (178) . The histological charges that accompany proximal renal tubular necrosis were also shown to be prevented by endothelin-1 antibody in the rat renal ischemia model (176, 179 ). An inhibitor of ECE-1, phosphoramidon, was also effective in preventing ischemia-induced ARF in animal models (180) . These findings provide direct and circumstantial evidence to suggest that endothelin-1 may be playing a pathogenic role in the development and/or maintenance of ARF.
More persuasive evidence has been obtained from studies with endothelin receptor antagonists. BQ-123 was shown to attenuate the renal functional impairment, tubular degenerative changes, and mitochondrial calcium accumulation in rats following bilateral renal artery occlusion when administered prior to the ischemic insult (181) . To date, the results indicate that ischemia-induced ARF is attenuated by the infusion of anti-endothelin antibody or a receptor antagonist during ischemia or the early phase of reperfusion. In a recent study, however, BQ-123 infused 24 hr after the onset of ischemia was shown to effectively reverse renal damage in rats with ARF, clearly indicating that an ETA antagonist is efficacious even in the treatment of established ARF (182) . Furthermore, since the negative actions of endothelin-1 on renal function in ARF are more marked during the maintenance phase than the initial phase after ischemia, endothelin receptor antagonists appear to be more effective in reversing than in preventing renal impairment (183, 184) . Thus, the survival rate was improved, and surviving animals exhibited a significant increase in glomelular filtration rate (GFR), decrease in plasma creatinine, and improvement in tubular function.
The potent inmunosuppressive agent cyclosporin has been extensively used primarily to prevent allograft rejection and to suppress a number of other diseases mediated by immunological mechanisms. Nephrotoxicity is one of the major side effects of cyclosporin and is characterized by renal vasoconstriction with peritubular capillary congestion and tubular toxicity (185) . Because of its potent and long-lasting vasoconstrictive actions, endothelin-1 was soon suspected to be involved in the cyclosporin nephrotoxicity (186, 187) . In fact, administration of cyclosporin to rats caused an increase in plasma endothelin-1 level with concomitant renal vasoconstriction and impaired renal function (188, 189) . Cyclosporin was also shown to increase renal endothelin receptor density and urinary endothelin excretion (190, 191) . Furthermore, both an endothelin receptor antagonist (BQ-123, PED-3512) and anti-endothelin-1 antiserum were effective in preventing the renal hemodynamic alterations induced by systemic administration of cyclosporin in rats (192, 193) . All these observations favor the view that cyclosporin may increase the renal endothelin production. In fact, in cultured endothelial cells and renal tubular epithelial cells, cyclosporin has been demonstrated to increase endothelin-1 synthesis and secretion (194) .
The exact role of endothelin-1 in chronic renal failure is obscure at present (195) . However, a study demonstrated that the selective ETA antagonist FR139317 reduced abnormal protein excretion, glomerular injury and renal cfos protooncogene expression, and prevented renal function deterioration when intraperitoneally administered once a day for up to 60 days in renal mass reduction rats (195) . The results suggest that endothelin receptor antagonists may also be useful in the treatment of progressive nephropathies.
V-4. Brain injury and cerebral vasospasm
A rare pathophysiological aspect of endothelin-1 is seen in wound-healing process in central nervous system (CNS) injury. When the CNS is injured, like in traumatic injury and cerebral ishemia, resting astrocytes transform to the reactive type (immature) from the mature type and proliferate to promote wound healing. Plasma-derived proteins and water exude into the CNS parenchyma from damaged brain capillaries. These pathological events simultaneously allow plasma-derived endothelin-1 to exude into injured tissues.
Endothelin-1 exerts a mitogenic action at a very low concentration (close to the plasma level) on differentiated astrocytes via dibutyryl cyclic AMP in vitro (82). The DNA synthetic activity in cultured astrocytes was markedly increased in the extract from brain tissue 24 hr after cold-injury but not in the extract from normal brain. This increase in DNA synthesis was significantly reduced by monoclonal anti-endothelin C-terminus antibody, which completely inhibited the astrocyte DNA synthesis induced by exogenous endothelin-1. These results suggest that injury-derived endothelin-1 in brain tissue might exert a mitogenic action on astrocytes (196) .
In the cold-injury model in rat cerebral cortex, the use of 125I-labeled endothelin-1 as a tracer clearly demonstrated that plasma endothelin-1 exuded into the brain parenchyma along with a breakdown of the blood-brain barrier (197) . Brain capillary endothelial cells also generate endothelin-1. The marked elevation of endothelin-1 level in the injured tissue (about 3 times the control level) is presumably attributable to these origins. In accordance with these events, astrocytes in the injured site rapidly reverted to the immature, RC 1 (a monoclonal antibody that recognizes radial glia and immature astrocytes)-positive cells, signalling the subsequent onset of cell proliferation. All of these events were observed in the acute phase of brain injury (24 hr after injury) (196) .
More direct evidence comes from observations in the spinal cord injury model in rats (198) . In the tissue 24 hr after stab injury of the spinal cord at the lower thoracic level with a needle, the level of endothelin-1 markedly rose to 30 times the control level. Simultaneously, astrocytes in the injured site entered the growth phase, exhibiting strong RC1-immunoreactivity and bromodeoxyuridine incorporation. Local injection of SB 209670 into the injured site dramatically inhibited such events (Fig.  9) . Fig. 9 . Inhibitory effect of SB 209670 on astrocyte response after spinal cord injury. Astrocytes in the injured site exhibited strong RC1-immunoreactivity and bromodeoxyuridine (BrdU) incorporation. These indicated that astrocytes entered into the growth phase. These responses were drastically reduced by a 10-yl injection of SB 209670 (5 mg/ml) 24 hr after the injury.
These findings clearly indicate that the endothelin-linitiated astrocyte response and the subsequent gliosis are essential and inevitable in the wound-healing process of damaged tissues. However, gliosis occasionally creates a physiological barrier to regenerating neuronal axons. It is thus fascinating that the use of SB 209670 in the acute phase of injury can determine the fate of gliosis.
In humans, endothelin-1 is detected not only in the reactive astrocytes of virus-infected brain, (e.g., herpes simplex encephalitis, progressive multifocal leukoencephalopathy and subacute sclerosing panencephalitis (199) ), but also in the reactive astrocytes of Alzheimer's disease brain (200) . The relationships between endothelin-1 and the pathophysiology of these diseases are quite intriguing but remain to be investigated.
Chronic cerebral vasospasm after subarachnoid hemorrhage (SAH) is a complex disease process characterized by marked persistent contraction of arterial smooth muscle followed by organic changes in the vessel wall (201) . Because of its potent and long-lasting constrictor action on cerebral arteries (202, 203) , much of the interest surrounding endothelin-1 in the central nervous system evolves around its putative role as a causative or modulatory factor of cerebral vasospasm. Elevated levels of endothelin-1 in the plasma and/or cerebrospinal fluid have been documented in patients suffering from acute cerebral events associated with cerebral artery spasm (204) (205) (206) (207) . The inhibition of mRNA transcription by actinomycin D greatly ameliorated the development of chronic cerebral vasospasm in dogs (208) , implying that endothelin-1 or other peptides may be involved in the pathogenesis of vasospasm. Furthermore, animal experiments have also suggested that ETA-receptor expression may be increased after SAH (209) and that cerebral vessels may be sensitized to the effects of endothelin-1 after SAH (210) . In addition to this indirect evidence, more direct demonstrations have been made in various animal models of cerebral vasospasm using endothelin receptor antagonists. In dogs (mostly double-hemorrhage model), cerebral vasospasm was effectively ameliorated by the following treatments: intracisternal administration of FR139317 (211) or phosphoramidon (212) , continuous intrathecal infusion of BQ-123 (209, 213) , intracisternal administration of SB 209670 (214) or intravenous administration of bosentan (215) . With respect to the pathogenesis of cerebral vasospasm, the attractively straightforward "endothelin hypothesis" appears to be supported by several different lines of experimental data, and suggests that an abluminal clot may stimulate endothelial cells in a cerebral artery to produce endothPlin-1
V-5. Vascular thickening
The enhanced production of endothelin-1 and the effectiveness of endothelin receptor antagonists have been demonstrated in a number of other diseases, such as acute myocardial infarction (216, 217) , neurogenic pulmonary edema (218) , and peptic ulcer (219, 220) . In addition to its acute vasoconstrictor effects, as already mentioned in the section on pulmonary hypertension, endothelin-1 is considered to exert chronic effects and to be deeply implicated in the proliferative responses associated with vascular diseases (221, 222) . Endothelin-1 has been reported to stimulate c fos, c jun and c-myc expression (223) ; increase the incorporation of [3H]-thymidine into DNA; and cause proliferation of vascular smooth muscle cells (224) , capillary endothelial cells (225) and fibroblasts (226) . In a study reported recently, endothelin-1 as well as angiotensin II was demonstrated to act as progression but not competence growth factors in vascular smooth muscle cells (227) . In vascular smooth muscle cells, furthermore, endothelin-1 induces the expression of mRNA encoding platelet-derived growth factor (PDGF) and TGF- (3 (228) . In addition to its direct mitogenic actions, a synergistic action exists between endothelin-1 and a wide variety of growth factors, including PDGF, basic fibroblast growth factor (bFGF), EGF, insulin and angiotensin II, suggesting that endothelin-1 may also function as a co-mitogen (229) (230) (231) . Other evidence suggests that an additional important role of endothelin-1 in the pathophysiology of vascular disease is in promotion of the synthesis and secretion of glycoproteins, thrombospondin, fibronection, and tenascin, thereby leading to the modification of extracellular constituents in cardiovascular tissues (232) .
Of particular interest in this connection, SB209670 strongly attenuated neointima formation following rat carotid artery balloon angioplasty (127, 233) . In angioplasty-induced neointima in rats, expressions of the mRNAs of endothelin-1, endothelin-3, ECE-1, ETA and ETB receptor were found to be increased (234) . Cultured vascular smooth muscle cells explanted from human coronary artery were shown to secrete considerable amounts of endothelin-1 and big endothelin-1 (235) . These results are highly suggestive that endothelin-1 may be involved in the development of restenosis following vascular angioplasty, particularly in the case of percutaneous transluminal coronary angioplasty (PTCA). However, the possibility of whether endothelin receptor antagonists are useful clinically to prevent stenosis following PTCA in humans still remains to be investigated.
Plasma endothelin-1 levels increased in parallel with the number of vascular beds involved with atherosclerotic disease in the aortic, coronary, renal and carotid vascular beds (236) . Positive staining of endothelin-1-like immunoreactivity was observed in endothelial and medial smooth muscle cells in atherosclerotic aorta. Oxidized low-density lipoprotein, a well-established atherogenic risk factor, has been shown to induce mRNA expression and release of endothelin-1 from human and porcine macrophage and endothelial cell cultures (237, 238) . Furthermore, systemic administration of endothelin-1 accumulates within the atherosclerotic plaques of hypercholesterolemic rabbits (239) . Enhanced endothelin-1 binding was also detected in hyperplastic lesions induced in pig femoral arteries and in atheromatous lesions of human coronary arteries and saphenous veins (240, 241) . FR139317 partially inhibited the endothelin-1 binding, suggesting that both ETA and non-ETA receptors may be expressed in atherosclerotic human coronary arteries. The cause and effect relationship between endothelin-1 and atherosclerosis is now under investigation.
V-6. Cardiac hypertrophy
Cardiac myocytes can divide only in the fetal period, and soon after birth, they lose their ability to replicate DNA. After birth, the heart grows by increase in size (hypertrophy) but not in cell number (hyperplasia). Even in adults, mechanical load or stretch in cardiac tissue has been identified as a growth stimulus and may be relevant in hypertension-induced cardiac hypertrophy (242) . Hypertrophy seems to be a fundamental adaptive response of the heart to an imposed work overload. Hormonal stimuli have also been postulated to play a role in the regulation of cardiac cell growth, e.g., thyroid hormone; either a-or ~-adrenergic agonists; and angiotensin II (243 -246) . Although there have been a large number of studies concerned with cardiac cell growth phenomena including hypertrophy, the mechanisms that contribute to cardiac cell growth still remain to be elucidated.
It is generally held that the velocity of shortening of cardiac fibers is modified to various degrees, depending on the inciting stimulus (247, 248) . In response to thyroxine administration, euthyroid rabbits (249) and hypophysectomized rats (250) have been demonstrated to synthesize the myosin isozyme with high ATPase activity (251) , which is closely related to the increase in the shortening velocity. Furthermore, cardiac hypertrophy also results in an increase in deposition of extracellular matrix proteins and in important remodeling of the cardiac interstitium that may ultimately result in a decrease in myocardial compliance (252) (253) (254) .
TGF-Q is one of the regulatory factors that control cell growth through regulation of the abundance and composition of the extracellular matrix (255, 256) . In fact, cardiac hypertrophy induced by pressure overload in rats was shown to be accompanied by an increase in expression of TGF-r3 mRNA, which was followed by the deposition of collagen (257, 258) . Cardiac hypertrophy is also associated with enhanced expression of proto-oncogenes (c-myc, c fos, etc.) at quite an early stage after the start of pressure overload (259, 260) .
It has been reported that the expression of myocardial endothelin-1 is induced in response to pressure overload on the left ventricle by aortic banding (261, 262) or on the right ventricle due to pulmonary hypertension (163), suggesting that the induction of myocardial endothelin may also be an early component of a generalized response to hemodynamic overload in the heart. This assumption is consistent with the fact that the preproendothelin-1 gene has the nucleotide sequences that conform with the consensus of the AP-1/Jun-binding element as well as the TPA-responsive element. Although there are several potential sources of endothelin-1 in the myocardium (263) , including large vessels and microvascular endothelial cells (264) , endocardium (265) and myocytes, indirect evidence suggests that the myocyte itself may be an important source. In myocytes of rats with pressure overload-induced hypertrophy, endothelin-l-mRNA was detected by in situ hybridization (262) . Furthermore, in cultured myocardium, mechanical stretch can induce endothelin-1 expression (266) . TGF-(3 (267), TNF-a (268), angiotensin II (265) and oxygen free radicals (264) appear to be concerned with the induction of myocardial endothelin expression. Angiotensin II also causes hypertrophy of the cultured myocytes, which is abolished by the coadministration of an ETA-receptor antagonist or treatment of the cells with antisense RNA for endothelin, suggesting that the growth-promoting effect of angiotensin II in cardiac myocytes is mediated by endothelin in an autooverload-induced cardiac hypertrophy was prevented by a selective ETA-receptor antagonist, BQ-123 (269), suggesting that the endothelin pathway may play a crucial role in the development of myocardial hypertrophy in vivo. V-7. Chronic heart failure Chronic heart failure (CHF) is one of the leading causes of death in many countries, and the five-year survival rate is only 25% in male patients once the diagnosis of CHF is made (270) . Occlusion of a coronary artery causes acute myocardial infarction in experimental animals, and survivors of acute myocardial infarction are at very high risk for the development of CHF (271) . Likewise, the incidence of CHF increases progressively in the years after myocardial infarction in humans (272) .
As myocardial performance deteriorates, systemic neurohumoral reflexes become operative to maintain cardiac output, organ perfusion and circulatory homeostasis. The renin-angiotensin axis, vasopressin and the sympathetic nervous system are activated. Although these reflexes are all adaptive responses, unfortunately, they appear to result in the augmentation of peripheral vascular tone, which becomes deleterious to the failing heart because it markedly increases afterload. These neurohumoral factors are also known to enhance endothelin-1 production in endothelial cells (vide supra, II-1).
In patients with chronic heart failure due to either idiopathic dilated cardiomyopathy or ischemic cardiomyopathy, a condition frequently associated with high plasma endothelin-1 concentration (273, 274) , intravenous infusion of bosentan, a nonpeptide endothelin receptor antagonist, was shown to produce marked improvement in hemodynamic parameters, with reductions in mean arterial, pulmonary arterial, right atrial and pulmonary artery wedge pressures, decreases in systemic and pulmonary vascular resistance, and a resultant increase in stroke volume and cardiac output (275) . These findings are clear evidence that endothelin-1 does contribute to the maintenance of vascular tone in such patients. Supporting evidence comes from observations in rats with heart failure one month after myocardial infarction induced by left coronary artery ligation, where it was shown that systemic infusion of BQ-123 decreased both myocardial contractility and heart rate (276) . Furthermore, in rats with infarction, the surviving myocardium expressed a markedly increased amount of endothelin-1 as well as its receptors (276) , suggesting that endogenous endothelin-1 might help to support cardiac function in the setting of myocardial failure through the upregulated endothelin system. In porcine heart subjected to ischemia by means of coronary artery occlusion, increased expression and production of endothelin-1 was detected in cardiac myocytes but not in coronary vascular endothelial or smooth muscle cells (277) . Upregulation of endothelin pathways may be beneficial in providing short-term inotropic support for the failing myocardium in which ~-adrenergic responsiveness is frequently attenuated.
However, it seems likely that prolonged stimulation by an upregulated endothelin system may have important maladaptive effects on myocardial structure and function, thereby leading to fatal events. In fact, rats that survived for more than 10 days after the left coronary artery ligation gradually died of severe congestive heart failure within the following several months, but continous infusion of BQ-123 by means of a subcutaneous osmotic minipump not only greatly improved the survival rate of rats but also ameliorated the left ventricular dysfunction and prevented harmful ventricular remodeling (an increase in the ventricular mass of the surviving myocardium and enlargement of the ventriclular cavity) (278) (Fig. 10) . Interestingly, in patients with acute myocardial infarction, which often leads to chronic heart failure, the plasma level of endothelin-1 seems to be an indicator of long-term prognosis; the higher the plasma level of endothelin-1, the higher the long-term mortality (279) . Thus, endothelin appears to cause progressive aggravation of the failing myocardium. Since endothelin-1 has direct toxic effects on cardiac myocytes (280, 281) , the increased endothelin-1 may lead to myocardial injury and contribute to the progression of CHF. Furthermore, as one of the maladaptive responses of the myocardium to endothelin, hypertrophy associated with the expression of a fetal gene program in myocytes is conceivable (282) . Such a change in myocyte phenotype might lead to the reduced expression of "adult" genes, such as SR Ca 2+ ATPase, that are critical to normal myocardial function. Another effect attributable to endothelin may be an acceleration of collagen synthesis in cardiac fibroblasts (283) that could contribute interstitial fibrosis, abnormal diastolic function of the myocardium, and impaired delivery of oxygen and nutrients to myocytes. This effect of endothelin-1 appears to be far more potent than that of angiotensin II (284) . Additionally, in patients with heart failure, the plasma level of endothelin correlated strongly with pulmonary artery pressure and pulmonary vascular resistance, suggesting that endothelin-1 is again an important mediator of reactive pulmonary hypertension due to heart failure (285). Accordingly, the inhibition of the upregulated myocardial endothelin system seems to be a novel and far more beneficial target for therapeutic intervention in CHF compared with just increasing cardiac contractility by classical cardiotonics. These findings suggest that interference with the endothelin-1 system by either specific receptor antagonists or endothelin-1 converting enzyme inhibitors may prove useful not only for the further delineation of the role of endogenous endothelin-1 in circulatory pathophysiology but also in new therapeutic approaches to conditions associated with high plasma or tissue levels of endothelin-1.
The discovery of endothelin in 1988 soon triggered explosive investigations of a worldwide scale, presumably due to its unusual characteristics; i.e., marked potency and long-lasting pressor actions. As a result, most of the basic problems concerned with the science of endothelin have rapidly been solved; e.g., features and regulations of the expression of endothelin genes, biosynthetic pathways including characterization and cloning of endothelin converting enzyme, pharmacological, biochemical and molecular-biological identification of endothelin receptor subtypes, intracellular signal transduction following receptor activation, and discovery of various receptor agonists and antagonists.
In addition to its potent cardiovascular actions, endothelin-1 shows a wide variety of biological effects, including contraction of nonvascular smooth muscle (intestinal, tracheal, broncheal, mesangial, bladder, uterine and prostatic smooth muscle), stimulation of neuropeptides, pituitary hormone and atrial natriuretic peptide release and aldosterone biosynthesis, modulation of neurotransmitter release, and increase of bone resorption. Furthermore, endothelin-1 has mitogenic properties and causes proliferation and hypertrophy of a number of cell types, including vascular smooth muscle cells, cardiac myocytes, mesangial cells, bronchial smooth muscle cells and fibroblasts. Endothelin-1 also induces the expression of several protooncogenes (c fos, C -Jun, c-myc, etc.). These actions, whereby endothelin-1 might influence the development of cellular hypertrophy/hyperplasia, are of potential significance in pathophysiological conditions associated with long-term changes in cardiovascular tissues, e.g., hypertension, myocardial infarction, chronic heart failure, vascular restenosis following balloon angioplasty, and atherosclerosis. These pathophysiological conditions are usually associated with increased plasma levels of endothelin-1, although the correlation is relatively poor. Nevertheless, a considerable increase in the tissue content of endothelin-1 has been gradually uncovered in many cases of these conditions. Even if the concentration of endothelin-1 at the cell surface is not high enough to induce contraction, it is well known that subthreshold concentrations of endothelin will enhance or potentiate the contraction produced by other vasoconstrictors (e.g., norepinephrine, serotonin, angiotensin II), indicating the existence of cross-talk among various vasoactive substances. Another important cross-talk among these substances may be mutual enhancement or inhibition of their expression in various tissues. In addition to these interactions, the true physiological and/or pathophysiological roles of each of the endothelin family peptide and receptor subtypes remain to be investigated. For this purpose, the potent and orally active endothelin receptor antagonists, as well as endothelin gene-manipulated animals, would be promising tools.
